Edition:
United Kingdom

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

20.20USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$20.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
56,919
52-wk High
$22.85
52-wk Low
$2.78

Latest Key Developments (Source: Significant Developments)

ProQR Q2 Loss Per Share Eur 0.23
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - ProQR Therapeutics NV ::PROQR ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 LOSS PER SHARE EUR 0.23.WITH CURRENT CASH ON HAND OF EUR 33.0 MILLION, AT JUNE 30, 2018, CO'S OPERATION IS FUNDED INTO LATE 2019.  Full Article

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Proqr reports loss of EUR 0.42 per share​
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Proqr Therapeutics Nv :Proqr announces results for the third quarter of 2017.Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​.  Full Article

ProQR Therapeutics prices public offering
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - ProQR Therapeutics Nv :ProQR prices approximately $20 million underwritten public offering and concurrent registered direct offering of ordinary shares.Pricing of offering of its ordinary shares at a price to public of $3.25 per share​.  Full Article

Proqr announces proposed public offering of ordinary shares
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Proqr Therapeutics Nv :Proqr announces proposed public offering of ordinary shares.Proqr - To use proceeds from both offerings to fund clinical trials, ongoing research & development activities​.  Full Article

ProQR doses first LCA 10 patient in clinical trial of QR-110
Monday, 13 Nov 2017 

Nov 13 (Reuters) - ProQR Therapeutics NV :ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness.ProQR Therapeutics - ‍interim safety and efficacy trial results for QR-110​ from majority of patients after 6 months of treatment are expected in 2018.ProQR Therapeutics - full 12 month treatment data for QR-110 from all patients are expected in 2019​.  Full Article

JDG B.V. reports 10.5 pct passive stake in ProQR Therapeutics NV as on Sept 14
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Proqr Therapeutics Nv :JDG B.V. Reports 10.5 percent passive stake in ProQR Therapeutics NV as on September 14 - SEC Filing‍​.  Full Article

UPDATE 1-ProQR soars as childhood blindness drug succeeds in early trial

Sept 5 Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision.